The French National Health Authority (HAS) officially approved the Novaxovid vaccine for COVID-19 on Friday, Trend reports citing Xinhua.
“Data from various studies show the high efficacy of the Novaxovid vaccine against symptomatic forms of COVID-19 (almost 90 percent), and especially against severe forms with an efficiency of nearly 100 percent,” the World Health Organization said in a statement.
HAS said Nuvaxovid, which is made by US biotech company Novavax, is suitable for people over the age of 18, with a three-week delay between doses.
The health authority said the Novaxovid vaccine can be used for those who have not received any shots, or cannot receive mRNA vaccines.
The French Ministry of Health said the first injections of Nuvaxovid could start in February, and it would receive 3.2 million doses in the first trimester. The first batch of vaccines will arrive at the end of January.